• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5498 | Ordered by Date (descending)
 1 2 3 ... 24 25 26 ... 53 54 55  

Deal: Collaboration or Financing	Date
Pronutria–Bertarelli Group: investment, 201510 investment €na by Gurnet Point Capital completing Pronutria’s Series C financing	2015-10-15
Curetis–SEVERAL: investment, 201510–201511 IPO €40m+€4.3m w 4m+431k new shares at €10/share at Euronext Amsterdam + Brussels	2015-10-14
Luxendo–EMBL: investment, 201510 financing round Series A totalling €6m co-led by EMBL Ventures + LSP	2015-10-14
Luxendo–Life Sciences Partners: investment, 201510 financing round Series A totalling €6m co-led by EMBL Ventures + LSP	2015-10-14
Luxendo–SEVERAL: investment, 201510 financing round Series A €6m co-led by EMBL Ventures + LSP	2015-10-14
Minoryx–Chiesi: investment, 201510 financing round Series A totalling €19.4m incl new investor Chiesi Ventures	2015-10-14
Minoryx–HealthEquity (ES): investment, 201510 financing round Series A totalling €19.4m incl existing investor HealthEquity	2015-10-14
Minoryx–Idinvest Partners: investment, 201510 financing round Series A totalling €19.4m incl new investor Idinvest Partners	2015-10-14
Minoryx–Kurma: investment, 201510 financing round Series A totalling €19.4m incl new investor Kurma Partners	2015-10-14
Minoryx–la Caixa: investment, 201510 financing round Series A totalling €19.4m incl existing investor Caixa Capital Risc	2015-10-14
Minoryx–Roche: investment, 201510 financing round Series A totalling €19.4m incl new investor Roche Venture Fund	2015-10-14
Minoryx–SEVERAL: investment, 201510 financing round Series A €19.4m led by Ysios Capital	2015-10-14
Minoryx–Ysios Capital: investment, 201510 financing round Series A totalling €19.4m incl lead investor Ysios Capital	2015-10-14
Zymeworks–Minapharm: GlymaxX technology, 201510– supply service cell line development for bispecific antibody production applying GlymaxX by ProBioGen	2015-10-14
Boehringer–Philogen: cancer immunotherapy, 201510– collab novel therapeutic concepts for treating AML	2015-10-12
Adheron Therapeutics–Abzena: antibody technology, 201510 existent lead product SDP051 uses Abzena’s Composite Human Antibody technology	2015-10-09
Adheron Therapeutics–Roche: investment, 201510 acquisition $105m upfront cash + $475m milestones	2015-10-09
Affimed–OTHER: investment, 201510 investment €19.2m purchase of 3.3m shares by existing shareholder	2015-10-09
NEO New Oncology–Akampion: public relations, 201510 service existent by Akampion	2015-10-09
NEO New Oncology–SEVERAL: investment, 201510 financing round €5m	2015-10-09
Glycotope–Octapharma: investment, 201510 acquisition of new shares by Octapharma as part of excl license deal	2015-10-08
Octapharma–Glycotope: protein expression technology, 201510– license ww excl to human coagulation factors based on GEX technology	2015-10-08
Merck (US)–Proteros: drug discovery services, 201510– collab €na upfront + research funding + $126m milestones + royalties r+d small mol cancer drug	2015-10-07
Nestlé–Lipotype: lipidomics research, 201510 collab existent use of Lipotype technology for lipid analysis in nutritional research NIHS	2015-10-07
Probiodrug–Rentschler: biological contract manufacturing, 201510– process developm + production of PBD-C06 for pre-clinical + clinical studies	2015-10-07
Marinomed–Austria (govt): investment, 201510 aws Mittelstandsfonds aquires share in Marinomed	2015-10-06
EMBL–IBM: software tools, 201510– supply EMBL deploys Aspera s/w for fast + reliable data transfer	2015-10-05
Fianostics–Sony: fluorescence immunoassay platform, 201510– collab contract manufacturing for MEF assay platform by Sony DADC BioSciences	2015-10-05
Affimed–Aeris Capital: investment, 201510 investment $21.8m for 3.3m shares by existing investor Aeris Capital	2015-10-01
Opti-Lab–Omnilab (DE): investment, 201510 acqu of additonal shares resulting in majority for Omnilab w sole minority owner now Sebastian Haselhun	2015-10-01
Roche–Arvinas: protein degradation drugs, 201510– strategic license multi-year for PROTAC technology to Genentech	2015-10-01
Tizona Therapeutics–Minapharm: GlymaxX technology, 201510– license + contract manufacturing agreem for use of GlymaxX for cancer antibody ProBioGen AG	2015-10-01
United States (govt)–Evotec: compound management, 201510–202009 supply service up to €4.5m to NCI Chemical Biology Consortium	2015-10-01
Sanofi–Pieris: anticalin technology, 2015Q3 collab existent developm of anti-infectives	2015-09-30
Asceneuron–SEVERAL: investment, 201509 financing round Series A CHF30m led by Sofinnova Partners	2015-09-29
Infinity Pharmaceuticals–Max Planck: drug discovery services, 201509– collab in cancer using LDC network with MPG + Helmholtz	2015-09-29
Zinc Ahead–Veeva Systems: investment, 201509 acquisition $130m in cash incl $10m deffered consideration over 3 years	2015-09-29
JnJ–Protectimmun: asthma drug, 201509 collab research JnJ Innovation funding preclinical study at Imperial College Protectimmune lead candidate	2015-09-28
Beijing Clear Biotech–Curetis: Unyvero platform, 201509– distribution excl in Greater China of system + 2 cartridges by BCB	2015-09-25
Nabriva–SEVERAL: investment, 201509 US IPO $92.25m with 9m ADSs at $10.25/ADS at Nasdaq	2015-09-23
Nestlé–AC Immune: Alzheimer test, 201509– collab r+d minimally invasive Tau Dx assay Néstle Institute of Health Sciences	2015-09-23
Zedira–Cardiff Univ: drug discovery, 201509– collab research role of transglutaminase 6 in disease pathway of cerebellar ataxia	2015-09-22
Qiagen–PathoFinder: molecular diagnostics, –201509 collab developm + production of RespiFast RG Panel for Rotor-Gene Q MDx instrument	2015-09-21
Biametrics–SEVERAL: investment, 201509 financing round Series A €3.1m from LBBW Venture + MBG BW + KfW	2015-09-18
French Myopathy Association–Cevec: cell line technology, 201509– license €na to use CAP GT technology for lentivirus cell line developm to Généthon	2015-09-17
Sigma-Aldrich–IROA Technologies: compound library, 201509– distribution ww excl of Mass Spectrometry Metabolite Library of Standards (MSMLS) by Sigma	2015-09-17
Taisho–Polyphor: drug discovery, 201509– collab €na identification of drug candidates using macrocycle platform	2015-09-17
Evolva–SEVERAL: investment, 201509 rights offering CHF57.4m	2015-09-16
Nestlé–Lipid Therapeutics: gastrointestinal drug, 201609– license excl to develop + market LT-02 ww excl Europe + Australia to Nestlé Health Science	2015-09-16
Forbion–SEVERAL: investment, 201509 closing €75m of FCF II Co-invest Fund I incl Coller Capital + Hamilton Lane + KLP	2015-09-10
IAVI–CureVac: mRNA technology, 201509– collab using RNActive technology to deliver HIV immunogens for developm of AIDS vaccines	2015-09-10
Lophius–SEVERAL: investment, 201509 financing round incl VRD GmbH + S-Refit + Wolf Biotech + Bayern Kapital + HTGF	2015-09-10
Venneos–High-Tech Gründerfonds: investment, 201509 seed financing round totalling €1m from HTGF + Max Planck + business angels + family offices	2015-09-10
Venneos–Max Planck: investment, 201509 seed financing round totalling €1m from HTGF + Max Planck + business angels + family offices	2015-09-10
Venneos–SEVERAL: investment, 201509 seed financing round €1m from HTGF + Max Planck + business angels + family offices	2015-09-10
Lophius–High-Tech Gründerfonds: investment, 201509 financing round incl VRD GmbH + S-Refit + Wolf Biotech + Bayern Kapital + HTGF	2015-09-09
Phenomenex–Tecan: automated liquid handling, 201509– collab co-marketing Strata + Strata-X SPE sorbents with Freedom EVO platform	2015-09-08
Pierre Fabre–Addex: CNS drugs, 201509– license option for mGlu3 receptor program to Pierre Fabre Pharmaceuticals	2015-09-08
Lumora–Erba Diagnostics Mannheim: investment, 201509 acquisition of Lumora Ltd renamed Erba Molecular Ltd	2015-09-07
ADC Therapeutics–Instinctif Partners: public relations, 201509 service existent by Instinctif Partners for ADCT	2015-09-02
ADC Therapeutics–SEVERAL: investment, 201509 financing round $80m of ADC Therapeutics incl Auven + AstraZeneca et al	2015-09-02
Baxalta–Novimmune: therapeutic antibodies, 201509– collab r+d €na bispecific antibodies for hemophilia A	2015-09-02
Boehringer–Vectron Biosolutions: gene expression technology, 201509– license non-excl to Vectron technology for use w BI e. coli production system	2015-09-01
Chemie Brunschwig–Link Technologies: reagents, 201509– distribution in Switzerland by Chemie Brunschwig AG	2015-09-01
Intellia Therapeutics–Novartis: investment, 201509 financing round Series B totalling $70m led by OrbiMed + incl co-investor Novartis	2015-09-01
Intellia Therapeutics–SEVERAL: investment, 201509 financing round Series B $70m led by OrbiMed HealthCare Fund Management	2015-09-01
Labfolder–SEVERAL: investment, 201509 financing round € 7-digit led by Charité Biomedical Fund (CBF-1)	2015-09-01
Pfizer–Evotec: drug discovery services, 201509– collab + license agreem 4 years to develop anti-fibrotics	2015-09-01
Hisun Pharmaceutical–IMD Natural Solutions: drug discovery, 201508– collab using IMD natural product lead discovery platform incl €4m investment	2015-08-31
IMD Natural Solutions–Hisun Pharmaceutical: investment, 201508 equity investment €4m as part of collab with Zhejiang Hisun Pharmaceutical Co Ltd	2015-08-31
GSK–LimmaTech Biologics: vaccines, 201508– collab at least 5y using former GlycoVaxyn technology to develop vaccines owned by GSK	2015-08-28
Immatics–Texas (govt): grant, 201508 launch of Immatics US Inc supported by $19.7m grant from CPRIT	2015-08-26
Immatics–Univ Texas: cell therapy, 201508– collab launch joint venture Immatics US Inc with MD Anderson to advance adoptive cellular therapies	2015-08-26
Merus–Novartis: investment, 201508 financing round Series C 1st tranche €na of up to €72.8m round incl existing investor Novartis Venture Fund	2015-08-26
Merus–SEVERAL: investment, 201508 financing round Series C 1st tranche €na of up to €72.8m round	2015-08-26
GeneWorks–Genetrix (ES): genomic reagents, 201508– distribution non-excl Sygnis TruePrime + SunScript RT products in Australia	2015-08-25
MorphoSys–Immatics: cancer immunotherapy, 201508– collab strategic alliance r+d using Xpresident + Ylanthio platforms	2015-08-25
Osthus–Dotmatics: bioinformatics, 201508– collab combined services + product offering for RnD IT for life sciences	2015-08-24
Roche–Lumora: nucleic acid purification, 201508 acquisition €na of Heat Elution purifition technoloyg assets by Roche	2015-08-24
Freudenberg–CMS: legal services, 201508 legal advice by CMS Hasche Sigle on acquisition of Hemoteq AG by Freudenberg Medical Europe GmbH	2015-08-21
Hemoteq–Freudenberg: investment, 201508 acquisition of 74.9% majority share in Hemoteq AG by Freudenberg Medical Europe GmbH	2015-08-21
Novartis–GSK: ofatumumab, 201508 acquisition of all rights to all indications for Arzerra for up to $1.034b by Novartis	2015-08-21
Nanodigmbio–Genetrix (ES): genomic reagents, 201508– distribution of Sygnis TruePrime + SunScript RT products in China by Nanodigmbio	2015-08-20
EBS Technologies–Earlybird: investment, 201508 financing round totalling €1.1m led by returning investors Earlybird + HTGF	2015-08-19
EBS Technologies–High-Tech Gründerfonds: investment, 201508 financing round totalling €1.1m led by returning investors Earlybird + HTGF	2015-08-19
EBS Technologies–PERSON: investment, 201508 financing round €1.1m led by Earlybird + HTGF plus 3 private investors incl R Christine	2015-08-19
EBS Technologies–SEVERAL: investment, 201508 financing round €1.1m led by Earlybird + HTGF plus 3 private investors incl R Christine	2015-08-19
Kapa Biosystems–Roche: investment, 201508 acquisition €na by Roche	2015-08-19
Celsus Therapeutics–SEVERAL: investment, 201508– private placement $75m net $70m of ADSs led by Deerfield	2015-08-18
Kuros–Huntsworth: public relations, 201508 service existent media relations by Citigate Dewe Rogerson	2015-08-18
Kuros–SEVERAL: investment, 201508 financing round CHF15m led by LifeCare Partners + Life Sciences Partners	2015-08-18
GeneWeave–Roche: investment, 201508– acquisition $190m upfront + $235m product related milestones	2015-08-13
Checkmate–Cytos Biotechnology: cancer immunotherapy, 201508– excl license to CYT003 + VLP technology for cancer $90m milestones + royalties	2015-08-12
Checkmate–SEVERAL: investment, 201508 financing round Series A $20m from Sofinnova Ventures + venBio	2015-08-12
Sanofi–Apeiron: cancer immunotherapy, 201508– collab r+d small-molecules of Evotec + Apeiron + Sanofi	2015-08-10
Sanofi–Evotec: cancer immunotherapy, 201508– collab r+d small-molecules of Evotec + Apeiron + Sanofi	2015-08-10
JenaValve–SEVERAL: investment, 201508 financing round $26.5m including Gimv	2015-08-07
Nomad Bioscience–Denka: investment, 201508–201708 acquisition up to €75m of 51% share in Icon Genetics GmbH + after 2y acquiring rest by Denka	2015-08-07
Sanofi–Evotec: drug discovery, 201508– collab research beta cell replacement therapy for diabetes	2015-08-07
Deutsche Biotech Innovativ–Kirchhoff Consult: public relations, 201508 service existent by Kirchhoff Consult AG	2015-08-06

 1 2 3 ... 24 25 26 ... 53 54 55  

Advertisement

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.